Grace Therapeutics, Inc. (GRCE)

Last Closing Price: 3.65 (2026-01-16)

Income from Continuous Operations (Annual)

Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.

Grace Therapeutics, Inc. (GRCE) had Income from Continuous Operations of $-9.57M for the most recently reported fiscal year, ending 2025-03-31.

Figures for fiscal year ending 2025-03-31
Income Statement Financials
--
$-9.57M
--
--
$16.68M
$-16.68M
$3.91M
$-12.77M
$-12.77M
$-9.57M
Income from Continuous Operations
$-9.57M
$-9.57M
$-9.57M
$-16.68M
$-16.67M
12.09M
12.09M
$-0.79
$-0.79
Balance Sheet Financials
$22.71M
$0.01M
$49.28M
$71.99M
$1.93M
--
$3.45M
$5.38M
$66.61M
$17.34M
$66.61M
13.72M
Cash Flow Statement Financials
$-14.90M
--
$14.03M
$23.00M
$22.13M
$-0.87M
$0.73M
--
--
Fundamental Metrics & Ratios
11.77
--
--
--
--
--
--
--
--
--
--
$-14.90M
--
--
--
--
--
--
--
-14.36%
-55.17%
-13.29%
-14.36%
$4.86
$-1.23
$-1.23